GET DAILY SIGNALSCryoport (CYRX) Delivers +14% Revenue Growth in Q3 2026 With First Positive EBITDA
Key Takeaways
- Cryoport reported third-quarter 2026 revenue of $50.2 million, up 14% year over year from $44.2 million.
- Revenue topped the consensus estimate of roughly $48.7 million, extending a streak of four consecutive quarterly revenue beats.
- The company posted an adjusted net loss of $0.25 per share, wider than the consensus estimate of a loss of roughly $0.17 to $0.19 per share.
- Cryoport reached positive adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) of $1.1 million, another step in its "pathway to profitability."
- Management raised full-year 2026 revenue guidance to a range of $197 million to $199 million, up from the prior $192 million to $196 million.
- Commercial cell and gene therapy (CGT) revenue grew 20% year over year, supported by a record 788 global clinical trials and 23 commercially approved therapies.
- For deeper context on this report, explore Major News, Today's Price Move, Price Targets, and Forecast on Tickeron's dedicated CYRX pages.
- For AI-driven trading ideas, explore Trending AI Robots.
Why These Results Matter in Context
Cryoport's quarterly results offer a window into the health of the broader cell and gene therapy supply chain, an industry the company serves with temperature-controlled logistics, biostorage, and cryogenic equipment. The report matters because it tests whether recent double-digit revenue growth is translating into a narrower path toward profitability — a key investor concern after years of operating losses. With management having raised guidance earlier in 2026 and signaled an expectation of positive adjusted EBITDA in the second half of the year, this quarter serves as an important checkpoint on the company's cost discipline, margin trajectory, and ability to convert its expanding clinical-trial pipeline into commercial revenue. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What the Numbers Show
For the third quarter of 2026, ended September 30, 2026, Cryoport reported total revenue of $50.2 million, a 14% increase from $44.2 million in the prior-year period and above the consensus estimate of approximately $48.7 million. Commercial cell and gene therapy revenue rose 20% year over year, reflecting continued maturation of the therapies the company supports.
On the bottom line, the company reported an adjusted net loss of $0.25 per share, which was wider than the consensus estimate of a loss of roughly $0.17 to $0.19 per share. This compares with a loss of $0.18 per share a year earlier. Cryoport has now missed consensus earnings per share (EPS) estimates in each of its last four quarters, even as it has consistently beaten on revenue.
Notably, Cryoport generated positive adjusted EBITDA of $1.1 million for the quarter, up from negative adjusted EBITDA a year ago and building on the first positive print reached earlier in 2026. The company held $393.1 million in cash, cash equivalents, and short-term investments as of September 30, 2026. Management also raised its full-year 2026 revenue outlook to a range of $197 million to $199 million.
How the Market Is Responding
Sentiment around Cryoport has improved markedly through 2026, with shares up roughly 74% year to date as of the earnings release, compared with a gain of about 12% for the S&P 500. Investors have increasingly rewarded the company's consistent top-line growth, its expanding commercial therapy count, and its progress toward positive adjusted EBITDA.
The earnings reaction, however, will hinge on how the market weighs two competing signals: a wider-than-expected quarterly loss against an upward revision to full-year revenue guidance and another quarter of positive adjusted EBITDA. While the bottom-line miss reflects ongoing investment in global supply chain capacity and stock-based compensation, the guidance raise and record clinical-trial support suggest demand fundamentals remain intact. Post-earnings price action will likely be driven by management's commentary on the pace of margin improvement and the ramp of new facilities.
What to Watch Going Forward
Investors should watch how Cryoport converts its deepening cell and gene therapy relationships into sustained commercial revenue. The company ended the quarter supporting a record 788 global clinical trials and 23 commercially approved therapies — a pipeline that management views as a long-term growth engine.
Margin progression remains a central theme. New BioServices capabilities at the Paris and Santa Ana, California facilities are expected to ramp through late 2026 and into 2027, and management has cautioned that these additions carry near-term margin impact before they contribute meaningfully to operating leverage. The trajectory of adjusted EBITDA will therefore be a key indicator of whether the "pathway to profitability" remains on track.
Other factors to monitor include commercial cell and gene therapy shipment volumes, new therapy approvals (which typically ramp gradually), demand for MVE cryogenic systems across the Americas, Asia-Pacific, and EMEA (Europe, the Middle East, and Africa), and any changes to full-year guidance when fourth-quarter results are reported. Foreign currency fluctuations and interest-rate sensitivity on the company's investment portfolio also remain relevant considerations.
My Experience With Tickeron’s AI Tools
I often turn to Tickeron’s AI Screener when analyzing names like Cryoport to quickly compare fundamentals, technical patterns, and peer performance across the life sciences sector. The tool has helped me surface relevant trade ideas and understand how CYRX stacks up against similar companies without spending hours on manual research. It is a practical addition to my workflow for staying on top of sector trends and volatility signals.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Aroon Indicator for CYRX shows an upward move is likely
CYRX's Aroon Indicator triggered a bullish signal on October 15, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 203 similar instances where the Aroon Indicator showed a similar pattern. In 177 of the 203 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +2.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where CYRX advanced for three days, in 213 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The 10-day RSI Indicator for CYRX moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In 17 of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at 81%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CYRX as a result. In 80 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for CYRX turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 48 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
CYRX moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CYRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
CYRX broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. CYRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 55 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.903) is normal, around the industry mean (2.596). CYRX has a moderately low P/E Ratio (-18.556) as compared to the industry average of (7.656). CYRX's Projected Growth (PEG Ratio) (62.128) is very high in comparison to the industry average of (5.110). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (4.437) is also within normal values, averaging (2.034).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CYRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of cryogenic logistics solutions to the life sciences industry
Industry OtherTransportation
Advertisement